Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3)
Key facts
- Who runs it
- Frantz Viral Therapeutics, LLC
- Where
- Ann Arbor, Cleveland, Fort Myers, Houston, and Mayfield Heights, United StatesSee the 7 sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 78 people, planned
- Started
- 9 Sept 2020
- Expected to end
- 31 Dec 2026
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Artesunate vaginal insert
- Placebo vaginal insert
- Record updated
- 2 October 2025
Who can take part
- Age
- 25 years to 100 years
- Sex
- Women only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Adult females age ≥ 25 years
- Capable of informed consent
- Any HPV genotype detectable by DNA test/HPV genotyping
- Colposcopically-directed, histologically confirmed tissue diagnosis of cervical high grade squamous intraepithelial lesions (CIN2, CIN3, or CIN2/3)
- Women of childbearing potential agree to use birth control through week17 of the study
- Weight ≥ 50kg
Who cannot take part
- Taking immunosuppressive medication
- Evidence of concurrent cervical adenocarcinoma in situ
- Concurrent malignancy except for nonmelanoma skin lesions, because treatment for other cancers have systemic effects
- Active autoimmune disease
- HIV seropositivity
- Pregnant and nursing women
- Immunocompromised subjects
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 25 and 100 years old?
This trial is currently available in United States.
- University of MichiganAnn Arbor, United StatesContact: Mubeenah SyedahTaking people
- Cleveland Clinic Fairview HospitalCleveland, United StatesContact: Donna WhiteTaking people
- Cleveland Clinic FoundationCleveland, United StatesContact: Donna WhiteTaking people
- Florida Gynecologic OncologyFort Myers, United StatesContact: Cami HansenTaking people
- The Harris Health System (L.B.J Hospital)Houston, United StatesContact: Jessica GallegosTaking people
- University of Texas, M.D. AndersonHouston, United StatesContact: Jessica GallegosTaking people
- Hillcrest HospitalMayfield Heights, United StatesContact: Donna WhiteTaking people
About the trial
What the trial wants to find out
This is a phase II double blind, placebo-controlled, randomized study of Artesunate vaginal inserts for the treatment of women who have cervical high grade intraepithelial neoplasia (CIN2/3).
The 2 groups in the trial
- Artesunate vaginal insertTreatment being tested
Participants will receive three 5-day cycles of artesunate vaginal inserts, 200mg/day, at week 0, week 2, week 4.
- Placebo vaginal insertsPlacebo, for comparison
Participants will receive three 5-day cycles of placebo vaginal inserts, at week 0, week 2, and week 4.
Treatment: Placebo vaginal insert
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase II Double Blind, Placebo-controlled, Randomized Trial of Artesunate Vaginal Inserts for the Treatment of Patients With Cervical Intraepithelial Neoplasia (CIN2/3)
- Criteria questions
- Built from NCT04098744, who can take part
- Record updated
- 2 October 2025